SYNTHETIC STUDIES ON TUMOR PROMOTERS & INHIBITORS

肿瘤促进剂的综合研究

• 批准号: 7601796
• 负责人: PAUL Anthony WENDER
• 金额: $ 0.9万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-30 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7601796
• 关键词: Biological; Biological Assay; Bioluminescence; Cells; Computer Retrieval of Information on Scientific Projects Database; Development; Drug Evaluation; Evaluation; Family Study; Funding; Grant; Hybrids; Institution; Lead; Malignant Neoplasms; Paclitaxel; Research; Research Personnel; Resistance; Resources; Route; Source; Time; Tissues; Tumor Promoters; United States National Institutes of Health; analog; base; cancer therapy; daphnane; design; extracellular; gnidimacrin; inhibitor/antagonist; laulimalide

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is directed at five specific aims: the synthesis of gnidimacrin, a potent lead for the treatment of cancer based on PKC targeting; the development of a general and flexible rout to anticancer leads in the daphnane family and study of their activity; the synthesis and biological evaluation of daphnane-tigliane hybrids; the synthesis and biological evaluation of laulimalide analogs, compounds active against taxol resistant cancers; the design, synthesis, and evaluation of drug and probe transporters involving a real time bioluminescence assay with a specific focus on transporter conjugates that are designed for selective cell or tissue entry based on activation by extracellular poteases.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 该项目有五个具体目标：合成格尼迪马林，这是一种基于 PKC 靶向治疗癌症的有效先导药物；开发瑞香家族中通用且灵活的抗癌先导化合物并研究其活性；瑞香-蒂利亚烷杂种的合成和生物学评价；月桂马内酯类似物、对紫杉醇耐药癌症具有活性的化合物的合成和生物学评价；药物和探针转运蛋白的设计、合成和评估，涉及实时生物发光测定，特别关注转运蛋白缀合物，这些转运蛋白缀合物设计用于基于细胞外磷酸酶的激活选择性进入细胞或组织。